ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1909

Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women

Xinyi Liu1, Cianna Leatherwood1, Sara K. Tedeschi1, Medha Barbhaiya2, Cameron Speyer1, Bing Lu3, Karen Costenbader1, Elizabeth Karlson1 and Jeffrey A. Sparks1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, prevention, rheumatoid arthritis (RA) and risk, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M101 ACR Abstract: Epidemiology & Pub Health II: RA Risk: Education, Obesity, Smoking, or Biomarkers? (1905–1910)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay or even prevent RA, but previous investigations were limited for definitive conclusions by short follow-up. Therefore, we investigated the impact and timing of smoking cessation on RA risk using two large prospective cohorts with lengthy follow-up.

Methods: We investigated smoking cessation and RA risk in the Nurses’ Health Study (NHS, 1976-2014) and the NHSII (1989-2015). Smoking exposure data and covariates were obtained prospectively by biennial surveys. Women self-reported RA and medical record review confirmed RA by ACR criteria. Serologic status of RA was validated by rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) by chart review. Using pooled data, Cox regression estimated HRs and 95%CIs for RA phenotypes (seropositive, seronegative) by smoking status and years since cessation adjusting for possible confounders. Among past smokers, we used restricted cubic spline curves to investigate years since cessation and risk of RA phenotypes compared to recent quitters.

Results: Among 230,732 women, we identified 1,528 incident RA cases (n=969 seropositive, n=559 seronegative) during 6,037,151 person-years of follow-up. In the NHS in 1988, mean age was 54.3 years (SD 7.2), 18.8% were current smokers, and 36% were past smokers. In the NHSII in 1989, mean age was 34.4 years (SD 4.7), 13% were current smokers, and 21% were past smokers. Compared to never smoking, current smoking increased risk for seropositive RA (multivariable HR 1.67, 95%CI 1.38,2.01), but not seronegative RA (HR 1.20, 95%CI 0.93,1.55, Table). A modestly elevated RA risk was still detectable for seropositive RA (multivariable HR 1.30, 95%CI 1.01,1.68) 30 years after quitting smoking compared to never smoking. After smoking cessation, seropositive RA risk decreased over time compared to recent quitters (0-2 years) (Figure). Among the subset of past smokers, there was a linear relation between years since smoking cessation and reduced risk for seropositive RA (p=0.002), but not seronegative RA (p=0.78). Compared to recent quitters (<5 years), those who quit >30 years ago had HR of 0.63 (95%CI 0.44,0.90) for seropositive RA.

Conclusion: In this large prospective study with up to 38 years of follow-up, past smokers had significantly reduced risk for seropositive RA after quitting smoking, although residual elevated risk for RA remained even 30 years after quitting compared to never smokers. These results provide evidence that sustained smoking cessation reduces RA risk.


Disclosure: X. Liu, None; C. Leatherwood, None; S. K. Tedeschi, None; M. Barbhaiya, RRF, 2; C. Speyer, None; B. Lu, None; K. Costenbader, None; E. Karlson, None; J. A. Sparks, None.

To cite this abstract in AMA style:

Liu X, Leatherwood C, Tedeschi SK, Barbhaiya M, Speyer C, Lu B, Costenbader K, Karlson E, Sparks JA. Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/impact-and-timing-of-smoking-cessation-on-reducing-risk-for-seropositive-rheumatoid-arthritis-among-women/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-and-timing-of-smoking-cessation-on-reducing-risk-for-seropositive-rheumatoid-arthritis-among-women/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology